Clinical significance of differential plasma proteins levels in the diagnosis of epithelial ovarian cancer

Figure 1 Differential expression levels in patients with benign ovarian masses (10 patients), epithelial ovarian cancer (50 patients), and healthy control (30 females). A: Cancer antigen 125; B: Human epididymis protein 4; C: Insulin-like growth factors-binding proteins 2; D: Thrombospondin 1 protein; E: Secreted phosphoprotein 1. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001. CA125: Cancer antigen 125; HE4: Human epididymis protein 4; IGFBP2: Insulin-like growth factors-binding proteins 2; SPP1: Secreted phosphoprotein 1; TSP1: Thrombospondin 1 protein.

Figure 2 Area under the receiver operating characteristic curve analysis to differentiate between epithelial ovarian cancer (50 patients) patients and healthy control (30 females). A: Cancer antigen 125 (CA125); B: Human epididymis protein 4; C: Insulin-like growth factors-binding proteins 2; D: Thrombospondin 1 protein; E: Secreted phosphoprotein 1 (SPP1); F: Combined CA125 + SPP1. CA125: Cancer antigen 125; HE4: Human epididymis protein 4; IGFBP2: Insulin-like growth factors-binding proteins 2; SPP1: Secreted phosphoprotein 1; TSP1: Thrombospondin 1 protein.